
    
      In the phase 1 portion of the study, escalating doses of 33A will be evaluated in combination
      with azacitidine, and a dose of 33A will be selected to proceed to phase 2. The phase 2
      portion of the study is randomized, double-blind and placebo-controlled; it is designed to
      compare the overall response rate (ORR) between 2 study arms.
    
  